Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
---|---|---|---|---|---|---|---|---|---|---|---|---|
HCC1806 | Alpelisib | 2 | 72 | 1.0 | 11213.0 | 11894.0 | 1643.3 | 0.0 | 0.959 | 0.943 | 2.856 | HCC1806 BYL719 0 2 72 |
HCC1806 | Alpelisib | 2 | 72 | 3.2 | 10596.3 | 11894.0 | 1643.3 | 0.505 | 0.921 | 0.891 | 2.856 | HCC1806 BYL719 0 2 72 |
HCC1806 | CAL-101 | 2 | 72 | 0.001 | 11230.8 | 11282.8 | 1643.3 | -3.0 | 0.997 | 0.995 | 2.779 | HCC1806 CAL101 0 2 72 |
HCC1806 | CAL-101 | 2 | 72 | 0.0032 | 11273.8 | 11282.8 | 1643.3 | -2.49 | 0.999 | 0.999 | 2.779 | HCC1806 CAL101 0 2 72 |
HCC1806 | CAL-101 | 2 | 72 | 0.01 | 11404.3 | 11282.8 | 1643.3 | -2.0 | 1.010 | 1.010 | 2.779 | HCC1806 CAL101 0 2 72 |
HCC1806 | CAL-101 | 2 | 72 | 0.032 | 11305.3 | 11282.8 | 1643.3 | -1.49 | 1.000 | 1.000 | 2.779 | HCC1806 CAL101 0 2 72 |
HCC1806 | CAL-101 | 2 | 72 | 0.1 | 11409.3 | 11282.8 | 1643.3 | -1.0 | 1.010 | 1.010 | 2.779 | HCC1806 CAL101 0 2 72 |
HCC1806 | CAL-101 | 2 | 72 | 0.32 | 11440.8 | 11282.8 | 1643.3 | -0.495 | 1.010 | 1.010 | 2.779 | HCC1806 CAL101 0 2 72 |
HCC1806 | CAL-101 | 2 | 72 | 1.0 | 11624.3 | 11282.8 | 1643.3 | 0.0 | 1.020 | 1.030 | 2.779 | HCC1806 CAL101 0 2 72 |
HCC1806 | CAL-101 | 2 | 72 | 3.2 | 11994.0 | 11282.8 | 1643.3 | 0.505 | 1.040 | 1.060 | 2.779 | HCC1806 CAL101 0 2 72 |
HCC1806 | Everolimus | 2 | 72 | 0.001 | 10053.0 | 12020.5 | 1643.3 | -3.0 | 0.879 | 0.836 | 2.871 | HCC1806 Everolimus 0 2 72 |
HCC1806 | Everolimus | 2 | 72 | 0.0032 | 9348.8 | 12020.5 | 1643.3 | -2.49 | 0.832 | 0.778 | 2.871 | HCC1806 Everolimus 0 2 72 |
HCC1806 | Everolimus | 2 | 72 | 0.01 | 9417.5 | 12020.5 | 1643.3 | -2.0 | 0.837 | 0.783 | 2.871 | HCC1806 Everolimus 0 2 72 |
HCC1806 | Everolimus | 2 | 72 | 0.032 | 9329.3 | 12020.5 | 1643.3 | -1.49 | 0.831 | 0.776 | 2.871 | HCC1806 Everolimus 0 2 72 |
HCC1806 | Everolimus | 2 | 72 | 0.1 | 9054.3 | 12020.5 | 1643.3 | -1.0 | 0.812 | 0.753 | 2.871 | HCC1806 Everolimus 0 2 72 |
HCC1806 | Everolimus | 2 | 72 | 0.32 | 9042.0 | 12020.5 | 1643.3 | -0.495 | 0.811 | 0.752 | 2.871 | HCC1806 Everolimus 0 2 72 |
HCC1806 | Everolimus | 2 | 72 | 1.0 | 8742.8 | 12020.5 | 1643.3 | 0.0 | 0.790 | 0.727 | 2.871 | HCC1806 Everolimus 0 2 72 |
HCC1806 | Everolimus | 2 | 72 | 3.2 | 8863.5 | 12020.5 | 1643.3 | 0.505 | 0.799 | 0.737 | 2.871 | HCC1806 Everolimus 0 2 72 |
HCC1806 | Pictilisib | 2 | 72 | 0.001 | 11432.3 | 11984.0 | 1643.3 | -3.0 | 0.967 | 0.954 | 2.866 | HCC1806 GDC0941 0 2 72 |
HCC1806 | Pictilisib | 2 | 72 | 0.0032 | 11408.5 | 11984.0 | 1643.3 | -2.49 | 0.966 | 0.952 | 2.866 | HCC1806 GDC0941 0 2 72 |
HCC1806 | Pictilisib | 2 | 72 | 0.01 | 11154.5 | 11984.0 | 1643.3 | -2.0 | 0.951 | 0.931 | 2.866 | HCC1806 GDC0941 0 2 72 |
HCC1806 | Pictilisib | 2 | 72 | 0.032 | 11917.8 | 11984.0 | 1643.3 | -1.49 | 0.996 | 0.994 | 2.866 | HCC1806 GDC0941 0 2 72 |
HCC1806 | Pictilisib | 2 | 72 | 0.1 | 11495.5 | 11984.0 | 1643.3 | -1.0 | 0.971 | 0.959 | 2.866 | HCC1806 GDC0941 0 2 72 |
HCC1806 | Pictilisib | 2 | 72 | 0.32 | 11380.8 | 11984.0 | 1643.3 | -0.495 | 0.964 | 0.950 | 2.866 | HCC1806 GDC0941 0 2 72 |
HCC1806 | Pictilisib | 2 | 72 | 1.0 | 10951.3 | 11984.0 | 1643.3 | 0.0 | 0.938 | 0.914 | 2.866 | HCC1806 GDC0941 0 2 72 |